The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets

[1]  V. Marzo.  The endocannabinoid system in obesity and type 2 diabetes , 2008, Diabetologia.

[2]  I. Matias,et al.  Endocannabinoids: Some Like it Fat (and Sweet Too) , 2008, Journal of neuroendocrinology.

[3]  Deepak L. Bhatt,et al.  Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. , 2008, JAMA.

[4]  R. Capasso,et al.  Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High‐fat Diet , 2008, Obesity.

[5]  L. Aronne,et al.  Rimonabant: New data and emerging experience , 2008, Current atherosclerosis reports.

[6]  A. Ottani,et al.  Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: Insulin and melanocortins , 2008, Neuropharmacology.

[7]  M. Nakata,et al.  Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors , 2008, Regulatory Peptides.

[8]  F. Bermúdez-Silva,et al.  Presence of functional cannabinoid receptors in human endocrine pancreas , 2008, Diabetologia.

[9]  P. Bernante,et al.  The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. , 2007, The Journal of clinical endocrinology and metabolism.

[10]  V. Marzo,et al.  Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men , 2007, International Journal of Obesity.

[11]  G. van Dijk,et al.  Low-carbohydrate diets affect energy balance and fuel homeostasis differentially in lean and obese rats. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[12]  M. Fasshauer,et al.  Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity , 2006, Diabetes.

[13]  F. Rodríguez de Fonseca,et al.  Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. , 2006, European journal of pharmacology.

[14]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[15]  F. Bermúdez-Silva,et al.  Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell , 2006 .

[16]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[17]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[18]  P. Soubrié,et al.  The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  S. Woods,et al.  Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[20]  D. Hardie,et al.  Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase* , 2005, Journal of Biological Chemistry.

[21]  B. Cravatt,et al.  Food for thought: endocannabinoid modulation of lipogenesis. , 2005, The Journal of clinical investigation.

[22]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[23]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[24]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[25]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[26]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[27]  S. Black,et al.  Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. , 2003, European journal of pharmacology.

[28]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[29]  D. Piomelli,et al.  A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding , 2002, The Journal of Neuroscience.

[30]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[31]  T. Kirkham,et al.  Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors , 1999, Psychopharmacology.

[32]  J. McGarry,et al.  Fatty acids, lipotoxicity and insulin secretion , 1999, Diabetologia.

[33]  G. Boden.  Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[34]  R. Unger.  Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications , 1995, Diabetes.

[35]  T. Saruta,et al.  α- and β-Cell Function in Obese Zucker (fa/fa) Rats: A Study with the Isolated Perfused Pancreas , 1994 .

[36]  D. Tillotson,et al.  Oscillations in cytosolic free Ca2+, oxygen consumption, and insulin secretion in glucose-stimulated rat pancreatic islets. , 1991, The Journal of biological chemistry.

[37]  E. Samols,et al.  Intra-islet regulation. , 1988, The American journal of medicine.